Broad federal rescheduling stalls through 2026 with no floor vote.

Predicted 2026-07-16 · Resolves 2026-12-31 · legislation · USA

72%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

Even if individual lawmakers support changing how the federal government classifies psychedelics, a full vote on the floor of the House or Senate is extremely unlikely by the end of 2026. Congress's schedule is packed, and the DEA (Drug Enforcement Administration) hasn't signaled support, which makes lawmakers reluctant to push it forward.

Resolution rule: YES if no floor vote is held in either the U.S. House or Senate on legislation rescheduling psilocybin, MDMA, or LSD out of Schedule I on or before 2026-12-31, per congress.gov roll-call and legislative-action records. Any recorded floor vote on such a bill resolves NO. Checked 2026-12-31.

DEA is not aligned and the legislative calendar is packed. No chamber will hold a floor vote on core-psychedelic rescheduling absent a completed FDA approval. Historically no such bill has reached a floor vote.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →